3,600 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by PDT Partners LLC

PDT Partners LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,600 shares of the medical research company's stock, valued at approximately $853,000.

Several other large investors also recently modified their holdings of the stock. Versant Capital Management Inc increased its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA in the 2nd quarter valued at about $27,000. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter worth approximately $27,000. Park Place Capital Corp bought a new position in shares of IQVIA in the third quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA during the second quarter valued at approximately $29,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the topic of a number of research analyst reports. Evercore ISI cut their price target on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Robert W. Baird reduced their target price on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research report on Friday, November 1st. Leerink Partners reaffirmed an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Barclays dropped their price target on IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $256.50.

IQVIA Stock Performance

NYSE:IQV traded down $1.01 during trading hours on Tuesday, reaching $200.78. The company had a trading volume of 1,608,896 shares, compared to its average volume of 1,179,482. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market cap of $36.44 billion, a PE ratio of 26.35, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The business's 50 day moving average price is $217.11 and its 200-day moving average price is $225.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.